A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)
Sponsor: Daiichi Sankyo
Listed as NCT06362252, this PHASE1/PHASE2 trial focuses on Extensive Stage-small Cell Lung Cancer and remains actively recruiting participants. Sponsored by Daiichi Sankyo, it has been updated 14 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 9 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .